CL2022001685A1 - Anticuerpo multiespecífico con especificidad de unión para il-13 e il-17 humanas - Google Patents
Anticuerpo multiespecífico con especificidad de unión para il-13 e il-17 humanasInfo
- Publication number
- CL2022001685A1 CL2022001685A1 CL2022001685A CL2022001685A CL2022001685A1 CL 2022001685 A1 CL2022001685 A1 CL 2022001685A1 CL 2022001685 A CL2022001685 A CL 2022001685A CL 2022001685 A CL2022001685 A CL 2022001685A CL 2022001685 A1 CL2022001685 A1 CL 2022001685A1
- Authority
- CL
- Chile
- Prior art keywords
- human
- multispecific antibody
- binding specificity
- specificity
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un anticuerpo multiespecífico que tiene especificidad para IL-13 humana, IL-17A humana y/o IL-17F humana. La invención se refiere además a métodos para producir el anticuerpo multiespecífico y a su uso terapéutico para el tratamiento de la dermatitis atópica y otras enfermedades.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1919061.0A GB201919061D0 (en) | 2019-12-20 | 2019-12-20 | Multi-specific antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022001685A1 true CL2022001685A1 (es) | 2023-05-26 |
Family
ID=69323008
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022001685A CL2022001685A1 (es) | 2019-12-20 | 2022-06-17 | Anticuerpo multiespecífico con especificidad de unión para il-13 e il-17 humanas |
CL2023002975A CL2023002975A1 (es) | 2019-12-20 | 2023-10-04 | Anticuerpo multiespecífico con especificidad de unión para il-13 e il-17 humanas |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023002975A CL2023002975A1 (es) | 2019-12-20 | 2023-10-04 | Anticuerpo multiespecífico con especificidad de unión para il-13 e il-17 humanas |
Country Status (19)
Country | Link |
---|---|
US (1) | US20230087378A1 (es) |
EP (1) | EP4077381A1 (es) |
JP (1) | JP2023507280A (es) |
KR (1) | KR20220117307A (es) |
CN (1) | CN114846026A (es) |
AR (1) | AR120818A1 (es) |
AU (1) | AU2020407279A1 (es) |
BR (1) | BR112022011627A2 (es) |
CA (1) | CA3164276A1 (es) |
CL (2) | CL2022001685A1 (es) |
CO (1) | CO2022009711A2 (es) |
EC (1) | ECSP22054471A (es) |
GB (1) | GB201919061D0 (es) |
IL (1) | IL294035A (es) |
MX (1) | MX2022007150A (es) |
PE (1) | PE20221173A1 (es) |
TW (1) | TW202130365A (es) |
WO (1) | WO2021123186A1 (es) |
ZA (1) | ZA202207715B (es) |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
ATE243745T1 (de) | 1994-01-31 | 2003-07-15 | Univ Boston | Bibliotheken aus polyklonalen antikörpern |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
DE19653722C2 (de) | 1996-12-10 | 2000-06-29 | Brose Fahrzeugteile | Beidseitig wirkende Verstellvorrichtung |
JP4108760B2 (ja) | 1997-02-21 | 2008-06-25 | ジェネンテック,インコーポレーテッド | 抗体フラグメント−ポリマー複合体およびヒト化抗il−8モノクローナル抗体 |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
DE69922159T2 (de) | 1998-01-23 | 2005-12-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Mehrzweck-antikörperderivate |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
JP2003518075A (ja) | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | 生理活性化合物の消失半減期延長のための方法及び組成物 |
JP4336771B2 (ja) | 2001-03-09 | 2009-09-30 | モルフォシス アーゲー | 血清アルブミン結合部分 |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
WO2004001064A2 (en) | 2002-06-21 | 2003-12-31 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
DE60305919T2 (de) | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
JP4603894B2 (ja) | 2002-12-03 | 2010-12-22 | ユセベ ファルマ ソシエテ アノニム | 抗体産生細胞を同定するためのアッセイ |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
US7989594B2 (en) | 2003-07-01 | 2011-08-02 | Celltech R & D Limited | Modified antibody fab fragments |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
NZ591252A (en) | 2006-03-17 | 2012-06-29 | Biogen Idec Inc | Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids |
ES2622460T3 (es) | 2007-09-26 | 2017-07-06 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
CN102574914A (zh) | 2009-07-16 | 2012-07-11 | 葛兰素集团有限公司 | 改进的抗血清清蛋白结合性单可变区 |
ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB0920324D0 (en) | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
RS59589B1 (sr) | 2010-11-05 | 2019-12-31 | Zymeworks Inc | Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu |
CA2823812C (en) * | 2011-01-14 | 2017-02-14 | Ucb Pharma S.A. | Antibody molecules which bind il-17a and il-17f |
WO2013068571A1 (en) | 2011-11-11 | 2013-05-16 | Ucb Pharma S.A. | Albumin binding antibodies and binding fragments thereof |
EP2797955A2 (en) | 2011-12-30 | 2014-11-05 | AbbVie Inc. | Dual variable domain immunoglobulins against il-13 and/or il-17 |
CA2937556A1 (en) | 2014-02-21 | 2015-08-27 | Genentech, Inc. | Anti-il-13/il-17 bispecific antibodies and uses thereof |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
GB201411420D0 (en) | 2014-06-26 | 2014-08-13 | Ucb Biopharma Sprl | Antibody constructs |
-
2019
- 2019-12-20 GB GBGB1919061.0A patent/GB201919061D0/en not_active Ceased
-
2020
- 2020-12-18 PE PE2022001104A patent/PE20221173A1/es unknown
- 2020-12-18 IL IL294035A patent/IL294035A/en unknown
- 2020-12-18 CN CN202080088815.3A patent/CN114846026A/zh active Pending
- 2020-12-18 MX MX2022007150A patent/MX2022007150A/es unknown
- 2020-12-18 JP JP2022534761A patent/JP2023507280A/ja active Pending
- 2020-12-18 EP EP20841688.3A patent/EP4077381A1/en active Pending
- 2020-12-18 AU AU2020407279A patent/AU2020407279A1/en active Pending
- 2020-12-18 TW TW109145000A patent/TW202130365A/zh unknown
- 2020-12-18 KR KR1020227024913A patent/KR20220117307A/ko unknown
- 2020-12-18 AR ARP200103551A patent/AR120818A1/es unknown
- 2020-12-18 CA CA3164276A patent/CA3164276A1/en active Pending
- 2020-12-18 US US17/786,996 patent/US20230087378A1/en active Pending
- 2020-12-18 BR BR112022011627A patent/BR112022011627A2/pt unknown
- 2020-12-18 WO PCT/EP2020/087046 patent/WO2021123186A1/en unknown
-
2022
- 2022-06-17 CL CL2022001685A patent/CL2022001685A1/es unknown
- 2022-07-11 CO CONC2022/0009711A patent/CO2022009711A2/es unknown
- 2022-07-12 ZA ZA2022/07715A patent/ZA202207715B/en unknown
- 2022-07-13 EC ECSENADI202254471A patent/ECSP22054471A/es unknown
-
2023
- 2023-10-04 CL CL2023002975A patent/CL2023002975A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112022011627A2 (pt) | 2022-09-13 |
MX2022007150A (es) | 2022-07-19 |
US20230087378A1 (en) | 2023-03-23 |
PE20221173A1 (es) | 2022-07-25 |
ZA202207715B (en) | 2024-01-31 |
CA3164276A1 (en) | 2021-06-24 |
JP2023507280A (ja) | 2023-02-22 |
ECSP22054471A (es) | 2022-08-31 |
AR120818A1 (es) | 2022-03-23 |
CN114846026A (zh) | 2022-08-02 |
KR20220117307A (ko) | 2022-08-23 |
EP4077381A1 (en) | 2022-10-26 |
WO2021123186A1 (en) | 2021-06-24 |
AU2020407279A1 (en) | 2022-08-11 |
IL294035A (en) | 2022-08-01 |
GB201919061D0 (en) | 2020-02-05 |
CO2022009711A2 (es) | 2022-07-19 |
CL2023002975A1 (es) | 2024-04-01 |
TW202130365A (zh) | 2021-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR128047A2 (es) | Moléculas de anticuerpos que se unen a il-17a e il-17f | |
PE20201341A1 (es) | Anticuerpos de union a gprc5d | |
PE20210488A1 (es) | Anticuerpos especificos para gucy2c y sus usos | |
CO2017013710A2 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t. | |
EA200900492A1 (ru) | Молекулы антител, которые связываются с il-17a и il-17f | |
PH12018501141A1 (en) | Multi-specific antibody molecules having specificity for tnf-alpha, il-17a and il-17f | |
CR20110631A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
UY31862A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
UY31861A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
BR112015023557A2 (pt) | proteínas de ligações dual específicas direcionadas contra tnfa | |
AR057224A1 (es) | Moleculas de anticuerpo que tienen especificidad para la il- 6 humana | |
CL2021002815A1 (es) | Usos de anticuerpos anti-il-17a/f (divisional 2018-01135) | |
MX359834B (es) | Resorte de lámina y método para fabricar el mismo que tiene secciones con diferentes niveles de dureza total. | |
AR114129A1 (es) | ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS | |
AR115288A1 (es) | Anticuerpos humanizados contra el psma | |
CR20230474A (es) | Anticuerpos anti-cd19 y estructuras car-t | |
EA201891594A1 (ru) | Антитела к il-17c | |
CL2023001509A1 (es) | Anticuerpos multiespecíficos y combinaciones de anticuerpos | |
CL2023002975A1 (es) | Anticuerpo multiespecífico con especificidad de unión para il-13 e il-17 humanas | |
CO2022008268A2 (es) | Anticuerpo con especificidad de unión para il-13 humana | |
AR106507A1 (es) | Métodos para el tratamiento de enfermedades dermatológicas y reumatoideas | |
CO2022015030A2 (es) | Anticuerpos anti-cd19 y sus usos | |
AR122715A1 (es) | Anticuerpos y métodos para tratar enfermedades asociadas a claudina |